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Abstract
Aims/hypothesis—We aimed to study the relationship between measures of adiposity, insulin
sensitivity and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the Diabetes Prevention
Program (DPP).
Methods—The DPP is a completed clinical trial. Using stored samples from this resource, we
measured BMI, waist circumference (WC), an insulin sensitivity index (ISI; [1/HOMA-IR]) and
NT-proBNP at baseline and at 2 years of follow-up in participants randomised to placebo (n=692),
intensive lifestyle intervention (n=832) or metformin (n=887).
Results—At baseline, log NT-proBNP did not differ between treatment arms and was correlated
with baseline log ISI (p<0.0001) and WC (p=0.0003) but not with BMI (p=0.39). After 2 years of
treatment, BMI decreased in the lifestyle and metformin groups (both p<0.0001); WC decreased in
all three groups (p<0.05 for all); and log ISI increased in the lifestyle and metformin groups (both
p<0.001). The change in log NT-proBNP did not differ in the lifestyle or metformin group vs the
placebo group (p>0.05 for both). In regression models, the change in log NT-proBNP was
positively associated with the change in log ISI (p<0.005) in all three study groups after adjusting
for changes in BMI and WC, but was not associated with the change in BMI or WC after adjusting
for changes in log ISI.
Conclusion/interpretation—Circulating NT-proBNP was associated with a measure of insulin
sensitivity before and during preventive interventions for type 2 diabetes in the DPP. This
relationship persisted after adjustment for measures of adiposity and was consistent regardless of
whether a participant was treated with placebo, intensive lifestyle intervention or metformin.
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Introduction
Natriuretic peptides are cardiac-derived hormones that influence ventricular remodelling,
salt and water homeostasis, and vascular tone [1]. Multiple epidemiological studies have
demonstrated low concentrations of atrial natriuretic peptide and B-type natriuretic peptide
(BNP) in obese [1, 2] and insulin-resistant individuals [3], as well as in individuals who later
developed type 2 diabetes [4, 5]. Understanding whether natriuretic peptides are primarily
associated with insulin resistance or obesity in individuals at high risk of type 2 diabetes
may elucidate further the metabolic role of these biomarkers in the development of the
disease.
The Diabetes Prevention Program (DPP) was a randomised clinical trial of lifestyle and
pharmacological interventions to prevent diabetes in high-risk, overweight or obese
individuals [6]. The main results of the DPP, published in 2002, were that both an intensive
lifestyle intervention and metformin lowered body weight, insulin resistance and diabetes
incidence relative to placebo [7]. The availability of stored samples from the DPP and
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random allocation to placebo or clinical interventions provided an opportunity to examine
the association between N-terminal pro-B-type natriuretic peptide (NT-proBNP; as a
representative natriuretic peptide), obesity and insulin sensitivity prior to and during
preventive therapies in a population at high risk of developing type 2 diabetes.
Methods
The DPP Research Group conducted a randomised clinical trial from 1996 to 2001 at 27
centres in the United States; full inclusion and exclusion criteria and study design issues
have been published [6]. The institutional review board at each centre approved the protocol,
and all participants gave written informed consent.
Measurements
Measurements were performed at baseline and at 2 years of follow-up. Previously aliquoted
serum samples stored in the DPP repository at −80°C since collection during the DPP trial
were thawed, spun and centrifuged for 5 min at 1500 rpm. NT-proBNP concentrations were
measured using a cobas e601 immunoanalyser and proBNP II assay (both Roche
Diagnostics, Indianapolis, IN, USA) in the Biomarker Research Laboratory/TIMI Clinical
Trials Laboratory at the Brigham and Women’s Hospital. NT-proBNP concentrations
measured at less than the limit of detection (5 pg/ml, affecting 187 samples at baseline, 12
samples at year 1 and 146 samples at year 2) were assigned a random number between 0 and
5 pg/ml. NT-proBNP values were loge-transformed (log NT-proBNP) to approximate a
normal distribution.
Laboratory measurements for fasting plasma glucose and fasting insulin were performed by
glucokinase and radioimmunoassay methods, respectively, during the DPP study [6, 8]. An
insulin sensitivity index (ISI) was derived by the reciprocal of HOMA-IR: (1/HOMA-IR =
22.5/[fasting glucose (mmol/l) × fasting insulin (pmol/L)]). The ISI was calculated at
baseline and follow-up, and was loge-transformed (log ISI) to approximate a normal
distribution.
Statistical analysis
Due to prior sample use for other biomarker studies in the DPP, the percentage of stored
samples missing for the NT-proBNP measurement varied across the treatment groups (for
baseline samples: placebo 30%, intensive lifestyle 15%, metformin 11%). Thus, to correct
for potential biases introduced by the non-random missingness of samples, an inverse
probability weighting (IPW) method was used in appropriate analyses [9]. Statistics with
IPW are weighted statistics with the weight being the inverse of the stratum-specific
sampling fraction. A combination of age categories (24–44 years, 45–60 years and >60
years), sex, diabetic status at the end of the DPP, and treatment group were used as sampling
strata for the baseline and change analysis. Due to a different number of samples at baseline
and follow-up, two sets of stratum-specific weights were used to provide estimates of NT-
proBNP at the two time points. The primary study results of treatment effect were restored
after using the IPW, demonstrating the effectiveness of the method. In the data analyses of
this manuscript, results with or without the IPW are not drastically different.
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General linear models were used to examine the association between change in log NT-
proBNP and change in both log ISI and a measure of adiposity (BMI or WC). These
multivariate models were adjusted for age, sex, self-reported race and ethnicity, and for
baseline log NT-proBNP, baseline log ISI, and baseline BMI or baseline WC.
All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA). Two-
sided p values are reported and statistical significance was set at α=0.05.
Results
Baseline characteristics of the 3,234 participants who enrolled in the DPP study are given in
Table 1. NT-proBNP at baseline was similar for directly measured and estimated values
using IPW for each study arm, respectively (median [interquartile range] in pg/ml): placebo
(33.4 [17.1–62.3] vs 32.8 [16.7–59.1]); intensive lifestyle intervention (30.9 [14.0–59.9] vs
30.4 [13.9–57.5]); metformin (29.7 [14.0–54.2] vs 29.5 [14.1–53.6]). Baseline log NT-
proBNP was correlated with baseline log ISI (+0.17, p<0.0001) and WC (−0.063, p=0.0003)
but not with baseline BMI (−0.015, p=0.39).
BMI (in kg/m2) decreased in the intensive lifestyle and metformin groups and did not
change in the placebo group (−1.93 ± 0.09, p<0.0001; −0.74 ± 0.07, p<0.0001; −0.00 ± 0.06,
p=1.00, respectively). WC (in cm) decreased in the intensive lifestyle, metformin and
placebo groups (−5.55 ± 0.23; −2.12 ± 0.22; −0.79 ± 0.21; all p<0.0001, respectively). Log
ISI (in log units) increased from baseline in the intensive lifestyle and metformin groups but
not in the placebo group (+0.21 ± 0.02, p<0.0001; 0.11 ± 0.02, p<0.0001; −0.041 ± 0.02,
p=0.51, respectively). The changes in log ISI, BMI and WC were all significantly different
in the intensive lifestyle or metformin group vs the placebo group (all comparisons
p<0.001).
Follow-up clinical information was available for 3,015 DPP participants. The median
change in NT-proBNP for each treatment group was similar whether measured directly or
estimated using IPW, respectively: intensive lifestyle intervention (3.19 pg/ml, n=832; 3.06
pg/ml, n=1079); metformin (1.45 pg/ml, n=887; 1.50 pg/ml, n=1073); placebo (1.33 pg/ml,
n=642; 1.16 pg/ml, n=1082). These changes in NT-proBNP, using IPW, represented
increases of 16.1%, 6.9% and 7.3% from baseline in the intensive lifestyle, metformin and
placebo groups, respectively. However, the change in log NT-proBNP in the intensive
lifestyle or metformin group did not differ from the change in the placebo group (p=0.16 and
p=0.46, respectively).
In statistical models adjusted for baseline traits and change in BMI or WC at follow-up, the
change in log NT-proBNP was associated with the change in log ISI for the placebo,
intensive lifestyle and metformin groups (p<0.005 for all three groups; Fig. 1). In the same
models adjusted for change in log ISI, the change in log NT-proBNP was not associated
with the change in BMI or WC in any of the treatment groups (p>0.05 for all; Fig. 1). The
point estimate of the relationship between log NT-proBNP and log ISI, BMI or WC from
multivariate models was similar across all study arms and did not differ between the placebo
group and the intensive lifestyle or metformin group (p>0.05 for all).
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Discussion
The present study is the first investigation of the natriuretic peptide system performed in the
context of a large-scale diabetes prevention trial. While change in NT-proBNP was not a
pre-specified endpoint of the DPP, we were able to use stored samples for our analyses. Our
principal finding is that NT-proBNP was associated with insulin sensitivity at baseline and
during preventive interventions for type 2 diabetes. This relationship persisted after
adjustment for measures of obesity and was consistent regardless of whether a participant
was treated with placebo, intensive lifestyle intervention or metformin. Together, these
results suggest that NT-proBNP is a robust marker of insulin sensitivity and is independent
of measures of obesity or preventive interventions for type 2 diabetes. Strengths of this study
include the large sample size; the well-phenotyped, multi-ethnic cohort; the randomised
allocation of lifestyle and pharmacological interventions; the inclusion of a placebo group;
and the standardised ascertainment of NT-proBNP on stored samples at baseline and follow-
up using a well-validated assay.
Limitations of our study also deserve comment. First, we did not measure natriuretic
peptides other than NT-proBNP in the DPP samples. We chose to measure NT-proBNP
because it is more stable in plasma and less influenced by acute haemodynamic changes
compared with mature BNP. Second, NT-proBNP was not a pre-specified endpoint of the
DPP and measurements were made on available samples, which themselves had non-random
proportions of missingness per intervention arm. Thus, statistical methods were needed to
estimate NT-proBNP within the intended randomised clinical trial design of the DPP. Third,
we did not have longitudinal measures of cardiac ejection fraction or other haemodynamic
measures. While rates of congestive heart failure and oedema were not increased in the
active treatment groups [10], this does not specifically exclude subclinical changes in
cardiac function or fluid retention nor other variables unaccounted for in our models that
may have influenced NT-proBNP concentrations.
In summary, NT-proBNP was associated with measures of insulin sensitivity before and
during preventive interventions for type 2 diabetes in the DPP. Higher concentrations of NT-
proBNP occurred in the context of greater insulin sensitivity. Given the potentially
favourable effects of natriuretic peptide signalling on metabolism, prospective studies are
warranted to assess whether directly altering BNP concentrations might influence metabolic
risk.
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Fig. 1.
Modelling change in log of NT-proBNP from baseline to follow-up by change in log of ISI
and change in BMI or change in WC. (a) The relationship (linear regression slopes and 95%
CI) between change in log NT-proBNP and change in BMI (black circles) or log ISI (black
triangles). (b) The relationship (linear regression slopes and 95% CI) between change in log
NT-proBNP and change in WC (black circles) or log ISI (black triangles). The point
estimates are similar across all treatment groups, suggesting that the relationship between
change in log NT-proBNP and change in BMI, WC or log ISI are consistent regardless of
the intervention. The 95% CIs for the relationship between change in NT-proBNP and BMI
or WC crosses 0 in all treatment groups, demonstrating no statistically significant
relationship. Predictors (change in log ISI, BMI and WC) are scaled by their SDs in all
regression models. All models were adjusted for age; sex; ethnicity; and baseline log NT-
proBNP, log ISI and BMI or WC
Walford et al. Page 9
Diabetologia. Author manuscript; available in PMC 2015 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Walford et al. Page 10
Table 1
Baseline characteristics of the DPP participants
Characteristic Placebo Intensive lifestyle intervention Metformin
n 1,082 1,079 1,073
Age, years 49.5 (43.1–57.3) 49.7 (42.2–58.5) 50.4 (43.9–57.3)
Female, n (%) 747 (69.0) 734 (68.0) 710 (66.2)
Ethnicity, n (%)
 White 586 (54.2) 580 (53.8) 602 (56.1)
 African-American 220 (20.3) 204 (18.9) 221 (20.6)
 Hispanic 168 (15.5) 178 (16.5) 162 (15.1)
 American Indian 59 (5.5) 60 (5.6) 52 (4.9)
 Asian 49 (4.5) 57 (5.3) 36 (3.4)
BMI, kg/m2 33.2 (28.9–37.7) 32.6 (28.9–37.2) 32.8 (29.1–37.3)
WC, cm 104.0 (94.8–114.0) 103.3 (94.8–113.4) 104.0 (94.5–113.3)
ISI 0.16 (0.11–0.24) 0.17 (0.11–0.24) 0.16 ( 0.11–0.24)
NT-proBNP, pg/mL 33.4 (17.1–62.3)a 30.9 (14.0–59.9)b 29.7 (14.0–54.2)c
Numbers are median (interquartile range) for continuous measures and n (%) for categorical measures
a
Baseline NT-proBNP measured in 762 participants
b
Baseline NT-proBNP measured in 916 participants
c
Baseline NT-proBNP measured in 959 participants
d
Baseline NT-proBNP measured in 583 participants
All other numbers are from the original DPP randomisation
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